Genertec Universal Medical Group Company Limited announced the successful completion of the second tranche of its 2026 domestic medium-term notes (T2 Notes) on 25 August 2026. The issuance was executed through its wholly-owned subsidiary, China Universal Leasing Co., Ltd., and raised the full targeted principal of RMB250 million.
The two-year T2 Notes, commencing 26 August 2026, carry a fixed annual coupon of 1.73% and were priced at par (RMB100.0 per note). The offering follows the board’s approval disclosed on 24 August 2026 and is part of the company’s 2026 medium-term note programme.
Genertec Universal Medical stated that all directors—comprising executive, non-executive and independent non-executive members—were in office as of the announcement date, 26 August 2026.
Comments